Research Article

Antiprotozoal and Antimycobacterial Activities of Pure Compounds from *Aristolochia elegans* Rhizomes

Adelina Jiménez-Arellanes,¹ Rosalba León-Díaz,¹ Mariana Meckes,¹ Amparo Tapia,² Gloria María Molina-Salinas,³ Julieta Luna-Herrera,⁴ and Lilián Yépez-Mulia²

¹ Unidad de Investigación Médica en Farmacología de Productos Naturales (UIMFPN), UMAE Hospital de Pediatría, Centro Médico Nacional Siglo XXI (CMN-SXXI), Instituto Mexicano del Seguro Social, (IMSS), 2° piso CORSE, 06720 México, DF, Mexico

² Unidad de Investigación Médica en Enfermedades Infecciosas y Parasitarias (UIMEIP), UMAE Hospital de Pediatría, CMN-SXXI, IMSS, 2° piso, 06720 México, DF, Mexico

³ División de Biología Celular y Molecular, Centro de Investigación Biomédica de Noreste (CIBIN), IMSS, 64720 Monterrey, NL, Mexico

⁴ Laboratorio de Inmunoquímica II, Departamento de Inmunoquímica, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, 11340 México, DF, Mexico

Correspondence should be addressed to Adelina Jiménez-Arellanes, adelinajim08@prodigy.net.mx

Received 24 August 2011; Revised 24 November 2011; Accepted 24 November 2011

Academic Editor: Vincenzo De Feo

Copyright © 2012 Adelina Jiménez-Arellanes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

We analyzed the antimycobacterial activity of the hexane extract of rhizomes from *Aristolochia elegans*. Some compounds of this extract were purified and tested against a group of drug-resistant *Mycobacterium tuberculosis* strains. We also evaluated their antiprotozoal activities. The hexane extract was active against *M. tuberculosis* H37Rv at a MIC = 100 µg mL⁻¹; the pure compounds eupomatenoid-1, fargesin, and (8R,8'R,9R)-cubebin were active against *M. tuberculosis* H37Rv (MIC = 50 µg mL⁻¹), while fargesin presented activity against three monoresistant strains of *M. tuberculosis* H37Rv and a MDR clinical isolate of *M. tuberculosis* (MIC < 50 µg mL⁻¹). Both the extract and eupomatenoid-1 were very active against *E. histolytica* and *G. lamblia* (IC₅₀ < 0.624 µg mL⁻¹); in contrast, fargesin and (8R,8'R,9R)-cubebin were moderately active (IC₅₀ < 275 µg mL⁻¹). In this context, two compounds responsible for the antimycobacterial presented by *A. elegans* are fargesin and cubebin, although others may exert this activity also. In addition to the antimycobacterial activity, the hexane extract has important activity against *E. histolytica* and *G. lamblia*, and eupomatenoid-1 is one of the compounds responsible for the antiparasite activity.

1. Introduction

Aristolochia elegans Mast (Aristolochiaceae) syn. *A. littoralis* is commonly known as guaco, duck flower, or elephant foot and is a perennial shrub cultivated as an ornamental plant in several parts of the world [1, 2]. The genus *Aristolochia* comprises ca. 400 species and is distributed in wide areas from tropical to temperate zones [3]. On the American continent, it is found from the south of the USA, throughout Mexico, the Caribbean, and Central America and as far as Argentina [4, 5]. *A. elegans* has been employed as an expectorant, an antitussive, an antiasthmatic, an analgesic, an antihistamine, and a detoxicant agent [3]. Moreover, *A. elegans* is

utilized as an antidote against snake bites and toothache, as a purgative, an insecticide, and as an antispasmodic [6]. In Mexican traditional medicine, this plant is used as antimicrobial, antitumoral, antidiarrheal, antipyretic, emmenagag agent, and anti-snake venom and for the treatment of scorpion poisoning [6, 7]. Alkaloids, lignans, neolignans, monoterpenoids, diterpenoids, sesquiterpenoids, tetralones, isoquinolines, porphyrins, biphenyl ethers, aristolactolactams, and aristolochic acid dimers have been isolated from the organic extracts or essential oil of leaves, stems, and roots of this species [2–5]. The hexane (Hex) and methanol (MeOH) extracts of *A. elegans* have proven to be moderately active against the venom of *Centruroides limpidus limpidus*,

and the mixture of hexanic extracts from *A. elegans* and *Bouvardia ternifolia* has improved their inhibitory effects up to 70% [6]. On the other hand, *A. elegans* ethanolic (EtOH) extract exhibited antimetabolic and antiviral activities [3, 8]. In a preliminary study, we focused on the analysis the activity of the Hex and MeOH extract (at 100 $\mu\text{g mL}^{-1}$) from the leaves, seeds, and rhizomes of *A. elegans* against *M. tuberculosis* H37Rv by radiorespirometric Bactec 460 assay. The Hex extract from leaves and seeds reduced the mycobacterium growth by less than 70%; however, with the Hex extract from the rhizome, a 99% inhibition of *M. tuberculosis* H37Rv growth was reached (data not published). Based on these data, we decided to investigate the antimycobacterial activity of the major compounds found in the Hex extract of *A. elegans*-rhizome.

In this paper, the isolation of (8R,8'R,9R)-cubebin, fargesin, and eupomatenoid-1 from the active Hex extract of *A. elegans* rhizome is described and their antimycobacterial activity against four monoresistant and two MDR *M. tuberculosis* strains is demonstrated. In addition, the activity of the isolated compounds was tested against the anaerobic protozoa: *Entamoeba histolytica* and *Giardia lamblia*.

2. Methods

2.1. General Experimental Procedures. The chemical characterization of the isolated compounds was determined by ^1H -NMR (Bruker-Avance F, 300 MHz) and ^{13}C -NMR (Variant Unity, 75.4 MHz) using Tetramethylsilane as an internal standard in CDCl_3 . Electron impact-mass spectra (EI-MS) were obtained on a Jeol AX-505 HA mass spectrometer at 70 eV. Melting points (m.p.) were determined with a Fisher-Johns apparatus and are uncorrected. Open Column chromatography (CC) was carried out by using silica gel 60 GF₂₅₄ (70–230 mesh, Merck) as a stationary phase, and silica gel 60 F₂₅₄ precoated aluminum plates (0.2 mm, Merck) were employed for analytical and preparative Thin Layer Chromatography (TLC) analysis. Hex, chloroform (CHCl_3), and MeOH were obtained from Mallinckrodt and J. T. Baker.

The spots were visualized by spraying it with a 10% solution of aqueous H_2SO_4 followed by heating at 100°C. High Performance Liquid Chromatography (HPLC) analyses were carried out with a Waters 600 system controller connected to a photodiode array detector 996, which was programmed to collect data from 220–380 nm at 2.4-nm resolutions. Control of equipment, data acquisition, and processing and the management of chromatographic information were performed by Millennium 32 software program (Waters). Analyses were accomplished on a Spherisorb S100DS2 RP column (4.6 $\times$ 250 mm, 10- μm particle size, Waters). The mobile phase comprised an isocratic MeOH system (HPLC grade, J. T. Baker), except for eupomatenoid-1 whose mobile phase was composed of acetonitrile/formic acid 98 : 2 (both HPLC grade, J. T. Baker). The flow rate was maintained constant at 0.3 mL min^{-1} for 30 min. Samples were solubilized in MeOH at 1 mg mL^{-1} , and a volume of 20 μL was injected.

2.2. Plant Material. *Aristolochia elegans*-rhizome was collected in Miahuatlan, Oaxaca State, Mexico, in November

2006. The plant was botanically identified by Abigail Aguilar, M.Sc., and a voucher specimen was deposited at the Herbarium of the Instituto Mexicano del Seguro Social, Mexico (IMSSM) with code number 16080.

2.3. Extraction and Isolation. Powdered air-dried rhizome (530 g) was macerated (3×48 h) with 5 L Hex at room temperature. The extract obtained was filtered and vacuum concentrated to yield 37 g of the crude extract. The Hex extract (35 g) was subjected to CC in silica gel (150 g) and was eluted with Hex : CHCl_3 (100 $\rightarrow$ 0) and CHCl_3 : MeOH (100 $\rightarrow$ 0), and 171 fractions of 125 mL each were obtained. Primary fractions (F1–F15) were combined according to a TLC analysis as follows: F1 (69 mg); F2 (10 mg); F3 (18 mg); F4 (92 mg); F5 (69 mg); F6 (149 mg); F7 (115 mg); F8 (434 mg); F9 (258 mg); F10 (322 mg); F11 (1,816 mg); F12 (1,218 mg); F13 (669 mg); F14 (14,109 mg); F15 (5,870 mg).

Fraction F5–F10 was submitted to preparative TLC employing Hex : CHCl_3 70 : 30 as an elution system; after this procedure, 53.5 mg of eupomatenoid-1 (**1**) was obtained with $R_f = 0.13$. On the other hand, primary fraction F14 (13 g) was subjected to repeated CC, utilizing silica gel (75 g) with solvent gradients of Hex : CHCl_3 (100 to 0) and CHCl_3 : MeOH (100 to 0). This process yielded 13 secondary fractions (FA–FM) of 150 mL each as follows: FA (9 mg); FB (11 mg); FC (69 mg); FD (10 mg); FE (304 mg); FF (819 mg); FG (1,351 mg); FH (794 mg); FI (3,239 mg); FJ (384 mg); FK (2,599 mg); FL (1,489 mg); FM (2,029 mg).

From secondary fractions FG and FH (2 g), fargesin (**2**) (607 mg) was isolated after successive CC and the recrystallization procedure with Hex. From secondary fraction FI (3 g), a mixture of fargesin and (8R,8'R,9R)-cubebin (**2** and **3**) was obtained and after successive CC and preparative TLC, 835.9 mg of **3** and 507.7 mg of **2** were purified.

Eupomatenoid-1 (**1**) was obtained as white crystalline needles with an m.p. of 157–158°C (lit, 154–156°C), soluble in CHCl_3 , with a retention time (R_t) = 13.09 min at 220 and 280 nm, and using a Hex : CHCl_3 1 : 1 system, it yielded a Retention factor (R_f) = 0.13. IR (KBr): 2,937, 2,849, 1,725, 1,604, 1,493, 1,448, 1,250, 1,142, and 1,041 cm^{-1} . IE-MS: m/z (rel. int) 322 (100), 295 (10), 291 (10), 202 (15), 121 (6), 77 (5), and 46 (15). ^1H -NMR (300 MHz, CDCl_3): 7.03 (1H, d, $J = 1.5$ Hz, H-4), 6.82 (1H, d, $J = 1.5$ Hz, H-6), 7.1 (1H, d, $J = 2$ Hz, H-2'), 7.25–7.32 (1H, d, $J = 8.2$ Hz, H-5'), 6.98 (1H, dd, $J = 8.2$ and 0.6 Hz, H-6'), 6.0 (2H, s, OCH_2O), 4.03 (3H, s, OCH_3), 2.40 (3H, s, 3- CH_3), 6.5 (1H, dd, $J = 15.6$ and 1.5 Hz, H α), 6.15–6.27 (1H, dq, $J = 15.6$ and 6.6 Hz, H β), and 1.91 (3H, dd, $J = 6.6$ and 1.5 Hz, H- γ). ^{13}C NMR (75.4 MHz, CDCl_3): 151.14 (C-2), 110.5 (C-3), 133.0 (C-3a), 133.6 (C-5), 109.2 (C-4), 104.4 (C-6), 177.8 (C-7), 142.1 (C-7a), 123.7 (C-1'), 109.4 (C-2'), 147.4 (C-3'), 147.9 (C-4'), 114.4 (C-5'), 120.6 (C-6'), 101.2 (OCH_2O), 56.2 (OCH_3), 9.6 (3- CH_3), 131.4 (C- α), 124.4 (C- β), and 18.4 (C- γ).

Fargesin (**2**) was obtained as a white powder with an m.p. of 136–139°C (lit, 137–139°C and 133–134°C), soluble in CHCl_3 , with an $R_t = 13.52$ min. at 220 and 280 nm, and showing $R_f = 0.56$ with a Hex : EtOAc 1 : 1 system. IR (KBr): 2,960, 2,870, 2,841, 1,606, 1,592, 1,512, 1,492, and 1,240 cm^{-1} . IE-MS: m/z (rel. int) 370 [M^+ (100)], 339 (12),

177 (40), 161 (40), 151 (15), 150 (10), 149 (45), 135 (30), and 122 (15). $^1\text{H-NMR}$ (300 MHz, CDCl_3): 6.76–6.9 (6H, m, H-2,5,6,2',5' and 6'), 4.73 (2H, d, $J = 4.0$ Hz, H-7 α and 7' α), 4.25 (2H, m, H-9 α and 9 β) 3.08 (1H, m, 8 and 8'), 3.86 (2H, m, H-9' α and 9' β), 5.95 (2H, s, OCH_2O), 3.89 (3H, s, OCH_3), and 3.86 (3H, s, OCH_3). $^{13}\text{C NMR}$ (75.4 MHz, CDCl_3): 101.0 (OCH_2O), 133.6 (C-1), 135.1 (C-1'), 106.5 (C-2), 108.2 (C-2'), 109.3 (C-5), 111.1 (C-5'), 118.2 (C-6), 119.3 (C-6'), 147.1 (C-3), 148.0 (C-3'), 148.7 (C-4), 149.2 (C-4'), 85.3 (7), 85.7 (C-7'), 54.3 (C-8), 71.7 (C-9), 71.7 (C-9'), 54.2 (C-8'), and 56.0 (2 OCH_3).

(8R,8'R,9R)-cubebin (**3**) was obtained as white needles with an m.p. of 127–128°C, soluble in CHCl_3 , with an $R_t = 14.85$ min. at 280 nm, and an $R_f = 0.37$ using a CHCl_3 system. IR (KBr): 3,365, 2,896, 1,611, 1,492, 1,441, 1,243, and 1,037 cm^{-1} . IE-MS: m/z (rel. int) 356 (30), 338 (30), 203 (40), 202 (15), 135 (100), and 81 (70). $^1\text{H-NMR}$ (300 MHz, CDCl_3): 6.49–6.73 (6H, m, H-2,5,6,2',5' and 6'), 5.92 and 5.91 (4H, s, 2 OCH_2O), 5.22 (1H, d, $J = 1.5$ Hz, H-9 α), 4.1 (1H, dd, $J = 8.7$, 6.9 Hz, H-9' α), 3.78 (1H, dd, $J = 8.7$, 7.2 Hz, H-9' β), 2.14 (2H, m, 8' and 8), 2.43 (2H, m, H-7 α and 7' α), 2.75 (1H, m, H-7 β), and 2.60 (1H, m, H-7' β). $^{13}\text{C NMR}$ (75.4 MHz, CDCl_3): 100.83 and 100.8 (OCH_2O), 133.2 (C-1), 134.1 (C-1'), 108.0 (C-2), 108.1 (C-2'), 109.15 (C-5), 109.3 (C-5'), 121.7 (C-6), 121.3 (C-6'), 147.6 (C-3), 147.5 (C-3'), 145.8 (C-4), 145.7 (C-4'), 38.4 (C-7), 39.1 (C-7'), 52.2 (C-8), 45.8 (C-8'), 103.3 (C-9), and 72.6 (C-9').

2.4. Test Organisms. *M. tuberculosis* strains H37Rv (ATCC 27294), four monoresistant variants of *M. tuberculosis* H37Rv, including isoniazid-resistant (ATCC 35822), streptomycin-resistant (ATCC 35820), rifampicin-resistant (ATCC 35838), and ethambutol-resistant (ATCC 35798), and two MDR clinical isolates of *M. tuberculosis* (CIBIN/UMF15:99 and SIN 4) were employed as mycobacterium testing organisms. *M. tuberculosis* H37Rv is sensitive to all five first-line anti-tuberculosis drugs (isoniazid, rifampicin, ethambutol, streptomycin, and pyrazinamide), and the two clinical isolates were MDR and resistant to all five first-line antituberculosis drugs. *Entamoeba histolytica* strain HM1-IMSS and *Giardia lamblia* strain IMSS:0989:1 were used as antiprotozoal testing organisms.

2.5. Antimycobacterial Activity. The Hex extract and pure compounds were tested using microplate Alamar blue assay (MABA), as previously described [9, 10]. All assays were carried out in triplicate, and isoniazid (0.06 $\mu\text{g mL}^{-1}$, Sigma) and rifampicin (0.062 $\mu\text{g mL}^{-1}$, Sigma) were included as positive control drugs to H37Rv-sensitive strains. For MDR *M. tuberculosis* (CIBIN/UMF15:99 and SIN 4), isoniazid and rifampicin were employed at 3.13 and 100.0 $\mu\text{g mL}^{-1}$, respectively. Ofloxacin at 0.5–16 $\mu\text{g mL}^{-1}$ was also used as a positive control by CIBIN/UMF15:99. Antimycobacterial activity was reported as the Minimal Inhibitory Concentration (MIC).

2.6. Antiprotozoal Activity. *E. histolytica* strain HM1-IMSS was cultured in a TYI-S-33-modified medium supplemented with 10% calf serum, and *G. lamblia* strain IMSS:0989:1

was maintained in a TYI-S-33 medium supplemented with 10% calf serum and bovine bile. *In vitro* susceptibility assays for both strains were performed by using the method previously described [11, 12]. Briefly, 5×10^4 trophozoites of *G. lamblia* were incubated for 48 h at 37°C with increasing concentrations of the Hex extract of *A. elegans* and the purified compounds. After incubation, *G. lamblia* trophozoites were washed and subcultured for an additional 48 h in fresh medium alone. For *E. histolytica*, 6×10^3 trophozoites were incubated for 72 h at 37°C with increasing concentrations of the samples tested. Dimethyl sulfoxide (DMSO) was used as a suitable solvent. Albendazole and metronidazole were included as positive controls; parasites without treatment were included as a negative control. *G. lamblia* and *E. histolytica* trophozoites were counted, and the 50% Inhibitory Concentration (IC_{50}) was calculated by Probit analysis. Experiments were carried out in triplicate and repeated at least twice. Eupomatenoid-1 was also evaluated against *Trichomonas vaginalis* strain GT9 following the same procedure as for *E. histolytica*.

3. Results

3.1. Chemical Characterization of the Purified Compounds. In this study, we describe the isolation of eupomatenoid-1 (**1**), fargesin (**2**), and (8R,8'R,9R)-cubebin (**3**) (Figure 1) from the Hex extract of *A. elegans* rhizomes by chemical fractionation on CC. Their structures were elucidated according to $^1\text{H-NMR}$, $^{13}\text{C-NMR}$, and MS data and were in agreement with those previously described in the literature. In the HPLC analysis, the eupomatenoid-1 showed an $R_t = 13.09$ min. using acetonitrile/formic acid 98:2 system, while fargesin and (8R,8'R,9R)-cubebin showed $R_t = 13.52$ and 14.85 min., respectively, when MeOH was employed; all compounds were detected at 220 and 280 nm.

3.2. Antimycobacterial and Antiprotozoal Evaluation. The antimycobacterial activity of the Hex extract and purified compounds determined by the MABA is depicted in Table 1. Although Hex extract and eupomatenoid-1 were inactive against *M. tuberculosis* H37Rv ($\text{MIC} > 100 \mu\text{g mL}^{-1}$), fargesin and (8R,8'R,9R)-cubebin exhibited good activity against this strain ($\text{MIC} = 50 \mu\text{g mL}^{-1}$). It is noteworthy that the Hex extract and compound **3** were active against the two MDR *M. tuberculosis* clinical isolates: CIBIN/UMF15:99, and SIN4 ($\text{MIC} = 50 \mu\text{g mL}^{-1}$), while compound **2** inhibited only the growth of SIN4 ($\text{MIC} = 50 \mu\text{g mL}^{-1}$). In addition, compound **2** was the most active against the monoresistant variants of *M. tuberculosis* H37Rv ($\text{MIC} = 12.5\text{--}25 \mu\text{g mL}^{-1}$) with the exception of the ethambutol-resistant strain ($\text{MIC} > 50 \mu\text{g mL}^{-1}$). Compounds **1** and **3** were moderately active against all monoresistant strains of *M. tuberculosis* H37Rv tested ($\text{MIC} = 100 \mu\text{g mL}^{-1}$).

The antiprotozoal activity of the Hex extract and of pure compounds **1–3** was tested against the anaerobic protozoa *E. histolytica* and *G. lamblia* (Table 1). It was observed that the Hex extract was active against these two parasites, exhibiting $\text{IC}_{50} = 0.235$ and $0.315 \mu\text{g mL}^{-1}$, respectively. On the other hand, compound **1** was the most active compound

FIGURE 1: Chemical structures of isolated compounds from *A. elegans* hexanic extract.

against *E. histolytica* and *G. lamblia*, achieving IC_{50} values of 0.624 and 0.545 $\mu\text{g mL}^{-1}$, respectively. Compounds 2 and 3 demonstrated moderate antiprotozoal activity with $IC_{50} < 275.00 \mu\text{g mL}^{-1}$ against both parasites. Because of its important antiprotozoal activity, eupomatenoid-1 was evaluated against *T. vaginalis*, showing an $IC_{50} = 0.840 \mu\text{g mL}^{-1}$.

4. Discussion

The presence of the lignans and neolignans in *A. elegans* has been described [2, 5]; however, in this study the presence of eupomatenoid-1 (neolignan), fargesin, and (8R,8'R,9R)-cubebin (lignans) has been described for the first time in

A. elegans rhizome. In this work, the analytical conditions that can be employed for detecting these compounds are also described.

Compound 1 has previously been isolated from *Eupomatia laurina*, *A. taliscana*, and *Caryodaphnopsis baviensis*, and a related compound, such as eupomatenoid-7, has been found in *A. taliscana* [13–17]. Compound 2 has been isolated from *Horsfieldia iryagedhi* (*Myristica horsfieldia*), *Piper sarmentosum*, *Magnolia biondii*, *Stauroanthus perforatus*, and *Aristolochia malmeana* [18–23]. Compound 3 has been isolated from related species such as *A. legasiana*, *A. malmeana*, *A. odoratissima*, and *A. pubescens* [21, 22, 24]. In fact, structurally similar compounds such as aristolegin A-C have been reported for the roots and stems of *A. elegans* [5].

Of the three pure compounds, fargesin (2) was the most active against the mycobacterium strains tested ($MIC < 50 \mu\text{g mL}^{-1}$); compound 3 showed activity against *M. tuberculosis* H37Rv and two MDR strains of *M. tuberculosis*. Eupomatenoid-1 (1) was slightly active against *M. tuberculosis* H37Rv, its monoresistant variants and two MDR *M. tuberculosis* clinical isolates, in comparison with eupomatenoid-7, a compound structurally similar to eupomatenoid-1, that we have previously demonstrated to be more active against the same strains with MIC values $< 25 \mu\text{g mL}^{-1}$ [16]. These data suggest that the methylenedioxy group in the eupomatenoid-1 molecule exerts a negative influence on its antimycobacterial activity, since eupomatenoid-7 does not possess this group and was more active against several mycobacterium strains; nevertheless, further structure-activity studies are needed to confirm this hypothesis.

It is noteworthy that fargesin was active against *M. tuberculosis* H37Rv, its monoresistant strains, and to a lesser degree against the MDR SIN4 isolate ($MIC < 50 \mu\text{g mL}^{-1}$); on the other hand some related compounds such as (+)-sesamin and horsfieldin (isolated from *Piper sarmentosum*) were inactive against the *M. tuberculosis* H37Rv strain ($MIC > 200 \mu\text{g mL}^{-1}$) [25]. The bacteriostatic activity of (8R,8'R,9R)-cubebin has been reported against *Streptococcus mitis*, *Enterococcus faecalis*, *Ostrinia nubilalis*, and *Anticarsia gemmatilis* [21, 24–27]. Interestingly, in this study it has been demonstrated that compound 3 was active against the two MDR *M. tuberculosis* clinical isolates tested showing a MIC value of $50 \mu\text{g mL}^{-1}$. Our data suggest that compounds 2 and 3 are two of the possible compounds responsible for the antimycobacterial activity exerted by the Hex extract of *A. elegans*-rhizome.

Current tuberculosis chemotherapy is prolonged (24 months), poorly effective, expensive, and is accompanied by severe side effects. Besides, the presence of MDR *M. tuberculosis* cases is rapidly increasing. MDR accounts for 5.3% of all TB cases reported around the world [28, 29], underlining the importance of using new alternatives in the treatment of tuberculosis. In this regard, medicinal plants have proven to be an important source of antimycobacterial compounds [28, 30–32]. In fact, it was demonstrated that purified compounds 2 and 3 showed significant activity against monoresistant and MDR *M. tuberculosis* strains.

A murine model of tuberculosis previously developed by Hernández-Pando et al. [33] could be further used to

TABLE 1: Antimycobacterial and antiprotozoal activities of the hexanic extract and pure compounds isolated from *A. elegans*.

Sample	MIC ($\mu\text{g mL}^{-1}$) <i>M. tuberculosis</i>							IC ₅₀ ($\mu\text{g mL}^{-1}$)	
	H37Rv	CIBIN/UMF15:99	SIN4	RIF-R	STR-R	INH-R	EMB-R	<i>E. histolytica</i>	<i>G. lamblia</i>
Hexanic extract	>100	50	50	ND	ND	ND	ND	0.235	0.315
Eupomatenoid-1	100	100	100	100	100	100	100	0.624	0.545
Fargesin	50	>100	50	25	25	12.5	>50	120.6	262.7
(8R,8'R,9R)-Cubebin	50	50	50	100	100	100	100	137.3	275.0
Rifampicin	0.06	>100	100	>25	0.06	0.06	0.06	—	—
Isoniazid	0.06	3.1	3.1	0.06	0.06	>25	0.06	—	—
Streptomycin	0.5	>100	>4	0.5	>8	0.5	0.5	—	—
Ethambutol	2.0	8	>16	1.0	1.0	1.0	>32	—	—
Ofloxacin	—	0.5	8.0	—	—	—	—	—	—
Metronidazole	—	—	—	—	—	—	—	0.060	0.210

H37Rv: sensitive strain to INH, RIF, EMB, STR, and pyrazinamide; CIBIN/UMF15:99: resistant strain to INH, RIF, EMB, STR, and pyrazinamide; SIN4: resistant strain to INH, RIF, EMB, STR, rifabutin, ethionamide, and ofloxacin; RIF-R: rifampicin-resistant; STR-R: streptomycin-resistant; INH-R: isoniazid-resistant and EMB-R: ethambutol-resistant. ND: no determined; MIC: minimum inhibitory concentration; IC₅₀: 50% inhibitory concentration. Data are means of three determinations.

determine the *in vivo* activity of compounds **2** and **3**, resulting in insights concerning their potential as antitubercular agents. On the other hand, the chemical structure of these compounds can be a prototype for the design and synthesis of new derivatives with enhanced antimycobacterial activity.

G. lamblia and *E. histolytica* are two of the most clinically important anaerobic protozoa that cause diarrheal disease worldwide. Recently, giardiasis was included in the “Neglected Disease Initiative”, estimating that 280 million people are infected each year with *G. lamblia* [34]. Therefore, this stimulated our interest in determining the potential activity of the Hex extract of *A. elegans*-rhizome and its purified compounds against these two protozoa. Metronidazole was included as a reference drug because it has been regarded as the choice drug for the treatment of giardiasis and amoebiasis, although it is not always effective and has severe side effects.

The Hex extract and eupomatenoid-1 were the most active against both *E. histolytica* and *G. lamblia*. It should be mentioned that metronidazole was just 1.4 and 4 times more potent than the Hex extract and 2.5 and 10 times more active than eupomatenoid-1, respectively. The antiprotozoal activity of eupomatenoid-1 needs to be supported by a demonstration of its efficacy in animal models as well as by a clear understanding of its action mechanisms.

Several studies supporting the use of natural products and their purified active compounds are an alternative treatment for gastrointestinal infections. In particular, the antiprotozoal activity of *Helianthemum glomeratum* Lag. and *Rubus coriifolius* Focke was demonstrated *in vitro* and *in vivo* [35, 36]. The *in vitro* activity of MeOH extract from *H. glomeratum* and *R. coriifolius* showed IC₅₀ = 62.92 and 77.82 $\mu\text{g mL}^{-1}$ against *G. lamblia*; in addition, in a mouse model of giardiasis, these extracts showed an ED₅₀ = 0.125 and 0.506 mg kg⁻¹, respectively [36]. The most active compound isolated from these plants was (–)-epicatechin, this compound showed an *in vitro* IC₅₀ = 1.6 $\mu\text{g mL}^{-1}$ against

G. lamblia and in a mouse model of giardiasis had an ED₅₀ = 0.072 $\mu\text{mol kg}^{-1}$.

The inappropriate short-term exposure and exposure to sublethal levels of metronidazole have induced parasite drug resistance. Eupomatenoid-1 may therefore be considered as an active principle or even a prototype molecule for the development of novel antiprotozoal agents with activity against metronidazole resistant parasites.

5. Conclusion

In this study, the activity of (8R,8'R,9R)-cubebin and fargesin, purified from the Hex extract of *A. elegans*-rhizome, was demonstrated against *M. tuberculosis* H37Rv, four monoresistant variants, and two MDR *M. tuberculosis* clinical isolates. Although eupomatenoid-1 showed poor antimycobacterial activity, it had significant antiprotozoal activity. These active compounds can be prototype molecules for the design and synthesis of new derivatives with enhanced antimycobacterial or antiprotozoal activity.

Is currently being evaluated, the acute and subacute toxicity of active compounds in a mouse model. Further *in vivo* studies may well support the antimycobacterial and antiprotozoal activities of *A. elegans*-rhizome purified compounds.

The antiprotozoal activity of neolignans and lignans has scarcely been described in the literature, and our results encourage further studies on this issue.

Conflict of Interests

The authors declare that they have no competing interest. All authors read and approved the final paper.

Acknowledgments

This study was supported by a Grant from the Instituto Mexicano del Seguro Social, projects FOFOI 2005/1/I/102, FIS 2006/1A/I/053 and from Consejo Nacional de Ciencia y Tecnología (CONACYT) 48339-M.

References

- [1] C. Cano and F. Marroquín, *Taxonomía de Plantas Superiores*, Editorial Trillas, México, 1994.
- [2] T. S. Wu, Y. L. Tsai, P. L. Wu, F. W. Lin, and J. K. Lin, "Constituents from the leaves of *Aristolochia elegans*," *Journal of Natural Products*, vol. 63, no. 5, pp. 692–693, 2000.
- [3] L. S. Shi, P. C. Kuo, Y. L. Tsai, A. G. Damu, and T. S. Wu, "The alkaloids and other constituents from the root and stem of *Aristolochia elegans*," *Bioorganic and Medicinal Chemistry*, vol. 12, no. 2, pp. 439–446, 2004.
- [4] R. Vila, R. Mundina, L. Muschietti et al., "Volatile constituents of leaves, roots and stems from *Aristolochia elegans*," *Phytochemistry*, vol. 46, no. 6, pp. 1127–1129, 1997.
- [5] T. S. Wu, Y. L. Tsai, A. G. Damu, P. C. Kuo, and P. L. Wu, "Constituents from the root and stem of *Aristolochia elegans*," *Journal of Natural Products*, vol. 65, no. 11, pp. 1522–1525, 2002.
- [6] J. E. Jiménez-Ferrer, Y. Y. Pérez-Terán, R. Román-Ramos, and J. Tortoriello, "Antitoxin activity of plants used in Mexican traditional medicine against scorpion poisoning," *Phytomedicine*, vol. 12, no. 1-2, pp. 116–122, 2005.
- [7] A. Argueta, L. Cano, and M. Rodarte, *Atlas de las Plantas de la Medicina Tradicional Mexicana*, vol. 2-3, Editorial Instituto Nacional Indigenista, México, 1st edition, 1994.
- [8] T. S. Wu, A. G. Damu, C. R. Su, and P. C. Kuo, "Terpenoids of *Aristolochia* and their biological activities," *Natural Product Reports*, vol. 21, no. 5, pp. 594–624, 2004.
- [9] B. U. Jaki, S. G. Franzblau, L. R. Chadwick et al., "Purity-activity relationships of natural products: the case of anti-TB active ursolic acid," *Journal of Natural Products*, vol. 71, no. 10, pp. 1742–1748, 2008.
- [10] A. Jiménez-Arellanes, M. Meckes, J. Torres, and J. Luna-Herrera, "Antimycobacterial triterpenoids from *Lantana hispida* (Verbenaceae)," *Journal of Ethnopharmacology*, vol. 111, no. 2, pp. 202–205, 2007.
- [11] R. Cedillo-Rivera, B. Chávez, A. González-Robles, A. Tapia, and L. Yépez-Mulia, "In vitro effect of nitazoxanide against *Entamoeba histolytica*, *Giardia intestinalis* and *Trichomonas vaginalis* trophozoites," *Journal of Eukaryotic Microbiology*, vol. 49, no. 3, pp. 201–208, 2002.
- [12] R. Argüello-García, M. Cruz-Soto, L. Romero-Montoya, and G. Ortega-Pierres, "Variability and variation in drug susceptibility among *Giardia duodenalis* isolates and clones exposed to 5-nitroimidazoles and benzimidazoles in vitro," *Journal of Antimicrobial Chemotherapy*, vol. 54, no. 4, pp. 711–721, 2004.
- [13] F. Abe, S. Nagafuji, T. Yamauchi et al., "Trypanocidal constituents in plants I. Evaluation of some Mexican plants for their trypanocidal activity and active constituents in Guaco, roots of *Aristolochia taliscana*," *Biological and Pharmaceutical Bulletin*, vol. 25, no. 9, pp. 1188–1191, 2002.
- [14] N. H. Anh, H. Ripperger, A. Porzel, T. van Sung, and G. Adam, "Neolignans from *Caryodaphnopsis baviensis*," *Phytochemistry*, vol. 46, no. 3, pp. 569–571, 1997.
- [15] R. G. Enríquez, M. A. Chávez, and W. F. Reynolds, "Phytochemical investigations of plants of the genus *Aristolochia*, 1. Isolation and NMR spectral characterization of eupomatenoid derivatives," *Journal of Natural Products*, vol. 47, no. 5, pp. 896–899, 1984.
- [16] R. León-Díaz, M. Meckes, S. Said-Fernández et al., "Antimycobacterial neolignans isolated from *Aristolochia taliscana*," *Memorias do Instituto Oswaldo Cruz*, vol. 105, no. 1, pp. 45–51, 2010.
- [17] R. W. Read and W. C. Taylor, "Constituents of *Eupomatia* species. V. The isolation of eupomatenoid-13 (a new neolignan), ($\pm$)-trans-dehydrodiisoeugenol, and other extractives from the bark of *Eupomatia laurina*," *Australian Journal of Chemistry*, vol. 32, no. 10, pp. 2317–2321, 1979.
- [18] A. L. Anaya, M. Macías-Rubalcava, R. Cruz-Ortega et al., "Allelochemicals from *Stauranthus perforatus*, a Rutaceous tree of the Yucatan Peninsula, Mexico," *Phytochemistry*, vol. 66, no. 4, pp. 487–494, 2005.
- [19] A. A. L. Gunatilaka, A. M. Y. de Silva, S. Sotheeswaran, and L. M. V. Tillekeratne, "Horsfieldin, a lignan and other constituents from *Horsfieldia iryaghedhi*," *Phytochemistry*, vol. 21, no. 11, pp. 2719–2723, 1982.
- [20] H. Kakisawa, Y. P. Chen, and H. Y. Hsü, "Lignans in flower buds of *Magnolia fargesii*," *Phytochemistry*, vol. 11, no. 7, pp. 2289–2293, 1972.
- [21] G. B. Messiano, L. Vieira, M. B. Machado, L. M. X. Lopes, S. A. de Bortoli, and J. Zukerman-Schpector, "Evaluation of insecticidal activity of diterpenes and lignans from *Aristolochia malmeana* against *Anticarsia gemmatilis*," *Journal of Agricultural and Food Chemistry*, vol. 56, no. 8, pp. 2655–2659, 2008.
- [22] A. Usubillaga, N. Khouri, S. Cedillo-Vaz, and E. Yibirin, "Antisnake venom effect of *Aristolochia odoratissima* L. aqueous extract on mice," *Acta Horticulture*, vol. 3, no. 677, pp. 85–89, 2006.
- [23] Y. Shen, E. C. K. Pang, C. C. L. Xue, Z. Z. Zhao, J. G. Lin, and C. G. Li, "Inhibitions of mast cell-derived histamine release by different *Flos Magnoliae* species in rat peritoneal mast cells," *Phytomedicine*, vol. 15, no. 10, pp. 808–814, 2008.
- [24] I. C. de Pascoli, I. R. Nascimento, and L. M. X. Lopes, "Configurational analysis of cubebins and bicubebin from *Aristolochia lagesiana* and *Aristolochia pubescens*," *Phytochemistry*, vol. 67, no. 7, pp. 735–742, 2006.
- [25] P. Tuntiwachwuttikul, P. Phansa, Y. Pootaeng-on, and W. C. Taylor, "Chemical constituents of the roots of *Piper sarmentosum*," *Chemical and Pharmaceutical Bulletin*, vol. 54, no. 2, pp. 149–151, 2006.
- [26] C. B. Bernard, J. T. Arnason, B. J. R. Philogène, J. Lam, and T. Waddell, "Effect of lignans and other secondary metabolites of the asteraceae on the mono-oxygenase activity of the european corn borer," *Phytochemistry*, vol. 28, no. 5, pp. 1373–1377, 1989.
- [27] M. L. Silva, H. S. Coimbra, A. C. Pereira et al., "Evaluation of Piper cubeba extract, (-)-cubebin and its semi-synthetic derivatives against oral pathogens," *Phytotherapy Research*, vol. 21, no. 5, pp. 420–422, 2007.
- [28] J. C. Palomino, D. F. Ramos, and P. A. da Silva, "New anti-tuberculosis drugs: strategies, sources and new molecules," *Current Medicinal Chemistry*, vol. 16, no. 15, pp. 1898–1904, 2009.
- [29] E. M. Zager and R. McNerney, "Multidrug-resistant tuberculosis," *BMC Infectious Diseases*, vol. 8, p. 10, 2008.
- [30] C. L. Cantrell, S. G. Franzblau, and N. H. Fischer, "Antimycobacterial plant terpenoids," *Planta Medica*, vol. 67, no. 8, pp. 685–694, 2001.
- [31] G. F. Pauli, R. J. Case, T. Inui et al., "New perspectives on natural products in TB drug research," *Life Sciences*, vol. 78, no. 5, pp. 485–494, 2005.
- [32] B. R. Copp and A. N. Pearce, "Natural product growth inhibitors of *Mycobacterium tuberculosis*," *Natural Product Reports*, vol. 24, no. 2, pp. 278–297, 2007.
- [33] R. Hernández-Pando, D. Aguilar-Leon, H. Orozco et al., "16 α -Bromoepiandrosterone restores T helper cell type 1 activity and accelerates chemotherapy-induced bacterial clearance in

- a model of progressive pulmonary tuberculosis,” *Journal of Infectious Diseases*, vol. 191, no. 2, pp. 299–306, 2005.
- [34] M. Lalle, “Giardiasis in the post genomic era: treatment, drug resistance and novel therapeutic perspectives,” *Infectious Disorders—Drug Targets*, vol. 10, no. 4, pp. 283–294, 2010.
- [35] E. Barbosa, F. Calzada, and R. Campos, “Antigiardial activity of methanolic extracts from *Helianthemum glomeratum* Lag. and *Rubus coriifolius* Focke in suckling mice CD-1,” *Journal of Ethnopharmacology*, vol. 108, no. 3, pp. 395–397, 2006.
- [36] E. Barbosa, F. Calzada, and R. Campos, “*In vivo* anti giardial activity of three flavonoids isolated of some medicinal plants used in Mexican traditional medicine for the treatment of diarrhea,” *Journal of Ethnopharmacology*, vol. 109, no. 3, pp. 552–554, 2007.